Lovenox Patent Re-Issuance Denied: Aventis To Submit Response Shortly

Aventis downplayed the significance of the PTO denial, and likened the expected back-and-forth process with the patent office to FDA “approvable” discussions. The company still expects PTO to re-issue the patent by year-end.